Tonix Pharmaceuticals Holding Corp. Common Stock (TNXP)
Stock · NASDAQ · Health Care
$6.06as of 10/16/2026
Price chart
Active signals
TNXP Signal Track Record
How signals performed across all stocks →What TNXP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -14.5% | 46% | October 5, 2026 |
| Bollinger Band Breakdown | 20 | -13.4% | 30% | July 14, 2026 |
| Bollinger Band Breakout | 20 | -14.1% | 25% | June 26, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -31.7% | 0% | August 31, 2026 |
| Any 20-session window (baseline) | -12.6% | 31% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatm…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 142
- Website
- www.tonixpharma.com/
Fundamentals
- 1-day range
- $6.02$6.56
- Market cap
- $185.71M
- P/E (trailing)
- —
- P/E (forward)
- -0.77
- EPS (trailing)
- $-12.92
- Dividend yield
- —
- Beta
- 1.86
- Avg. volume
- 604.0K
- Dividend pay date
- November 1, 2019
How Tonix Pharmaceuticals Holding Corp. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Tonix Pharmaceuticals Holding Corp. Common Stock Competitors
Chosen by industry and closest market cap.
- TNXPTonix Pharmaceuticals Holding Corp. Common Stock$6.04▼ 5.92%Market cap $185.71MP/E —$6.01$20.69
- LFCRLifecore Biomedical Inc. Common Stock$6.38▼ 0.93%Market cap $181.55MP/E —$3.63$8.98
- CRBPCorbus Pharmaceuticals Holdings Inc. Common Stock$4.52▲ 4.39%Market cap $180.46MP/E —$4.23$20.56
- DERMJourney Medical Corporation Common Stock$4.97▼ 3.12%Market cap $179.80MP/E —$4.31$9.56
- ORMPOramed Pharmaceuticals Inc. Common Stock$4.07▼ 2.63%Market cap $178.87MP/E 0.98$2.09$5.47
- NBPNovaBridge Biosciences American Depositary Shares$1.26▼ 2.33%Market cap $196.15MP/E —$1.26$6.79
- KRROKorro Bio Inc. Common Stock$8.49▼ 8.81%Market cap $174.80MP/E —$5.2$55.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding Corp. Common Stock | $185.71M | — | $6.04 | ▼ 5.92% | $6.01$20.69 |
| LFCR Lifecore Biomedical Inc. Common Stock | $181.55M | — | $6.38 | ▼ 0.93% | $3.63$8.98 |
| CRBP Corbus Pharmaceuticals Holdings Inc. Common Stock | $180.46M | — | $4.52 | ▲ 4.39% | $4.23$20.56 |
| DERM Journey Medical Corporation Common Stock | $179.80M | — | $4.97 | ▼ 3.12% | $4.31$9.56 |
| ORMP Oramed Pharmaceuticals Inc. Common Stock | $178.87M | 0.98 | $4.07 | ▼ 2.63% | $2.09$5.47 |
| NBP NovaBridge Biosciences American Depositary Shares | $196.15M | — | $1.26 | ▼ 2.33% | $1.26$6.79 |
| KRRO Korro Bio Inc. Common Stock | $174.80M | — | $8.49 | ▼ 8.81% | $5.2$55.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Tonix Pharmaceuticals To Present On Mpox Vaccine TNX-801 At World Vaccine Congress Europe On October 21benzinga · 10/15/2026
- Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property RightsBenzinga · 10/2/2026
- Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®Yahoo · 9/22/2026
- Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYABenzinga · 9/22/2026
- Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial NearsYahoo · 9/12/2026
Insider Activity
Insider Actions →- Seth Lederman · August 27, 2026 · Buy2.0K @ $13.79
- Richard H. Bagger · August 20, 2026 · Buy1.0K @ $12.6
- Bradley Saenger · June 30, 2026 · J1.5K @ $10.91
- Carolyn E. Taylor · June 12, 2026 · Buy1.4K @ $10.55
- Seth Lederman · June 9, 2026 · Buy5.0K @ $11.79
- Richard Newcomb Stillwell · June 8, 2026 · Buy5.0K @ $11.65
- Richard Newcomb Stillwell · May 12, 2026 · Grant22.7K
- Margaret Smith Bell · May 12, 2026 · Grant22.7K
- Hunter James Randolph Jr · May 12, 2026 · Grant22.7K
- James Treco · May 12, 2026 · Grant22.7K
- Carolyn E. Taylor · May 12, 2026 · Grant22.7K
- Richard H. Bagger · May 12, 2026 · Grant22.7K
- GRANGE DAVID L · May 12, 2026 · Grant22.7K
- Adeoye Y. Olukotun · May 12, 2026 · Grant22.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 4.97M
- Total value held
- $68.14M
- Institutional holders
- 78
- Unknown968.2K
- Unknown518.6K
- Unknown511.8K
- Unknown452.1K
- Unknown313.3K
- Unknown313.1K
- Unknown231.7K
- Unknown230.6K
- Unknown219.7K
- Unknown161.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TNXP Secures Second Medicare Agreement for TONMYA
Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.
TNXP Secures Second Medicare Agreement for TONMYA. Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.